Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After ST-Elevated Acute Myocardial Infarction (EPOC-AMI) - A Pilot, Randomized, Placebo-Controlled Study

被引:70
作者
Taniguchi, Norimasa [2 ]
Nakamura, Takeshi
Sawada, Takahisa
Matsubara, Kinya [3 ]
Furukawa, Keizo [3 ]
Hadase, Mitsuyoshi [4 ]
Nakahara, Yoshifumi [4 ]
Nakamura, Takashi [1 ,4 ]
Matsubara, Hiroaki
机构
[1] Kyoto Prefectural Univ Med, Dept Cardiovasc Med, Kamigyo Ku, Kyoto 6028566, Japan
[2] Sakurakai Takahashi Hosp, Dept Cardiol, Kobe, Hyogo, Japan
[3] Kyoto City Hosp, Dept Cardiol, Kyoto, Japan
[4] Saiseikai Shigaken Hosp, Dept Cardiol, Ritto, Japan
关键词
Acute myocardial infarction; Cardiac function; Erythropoietin; LEFT-VENTRICULAR FUNCTION; ANALOG DARBEPOETIN-ALPHA; HEART-FAILURE; ANGIOPLASTY; ACTIVATION; MICE; AKT; EXPRESSION; SURVIVAL; RECEPTOR;
D O I
10.1253/circj.CJ-10-0267
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Erythropoietin (EPO) enhances re-endothelialization and anti-apoptotic action. Larger clinical studies to examine the effects of high-dose EPO are in progress in patients with acute myocardial infarction (AMI). Methods and Results: The aim of this multi-center pilot study was to investigate the effect of low-dose EPO' (6,000 IU during percutaneous coronary intervention (PCI), 24h and 48h) in 35 patients with a first ST-elevated AMI undergoing PCI who was randomly assigned to EPO or placebo (saline) treatment. Neointimal volume, cardiac function and infarct size were examined in the acute phase and 6 months later (ClinicalTrials.gov identifier: NCT00423020). No significant regression in in-stent neointimal volume was observed, whereas left ventricular (LV) ejection fraction was significantly improved (49.2% to 55.7%, P=0.003) and LV end-systolic volume was decreased in the EPO group (47.7 ml to 39.0 ml, P=0.036). LV end-diastolic volume tended to be reduced from 90.2% to 84.5% (P=0.159), whereas in the control group it was inversely increased (91.7% to 93.7%, P=0.385). Infarction sizes were significantly reduced by 38.5% (P=0.003) but not in the control group (23.7%, P=0.051). Hemoglobin, peak creatine kinase values, and CD34(+)/CD133(+)/CD45(dim) endothelial progenitors showed no significant changes. No adverse events were observed during study periods. Conclusions: This is a first study demonstrating that short-term low-dose' EPO to PCI-treated AMI patients did not prevent neointimal hyperplasia but rather improved cardiac function and infarct size without any clinical adverse effects. (Circ J 2010; 74: 2365-2371)
引用
收藏
页码:2365 / 2371
页数:7
相关论文
共 42 条
[21]   A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction [J].
Hare, Joshua M. ;
Traverse, Jay H. ;
Henry, Timothy D. ;
Dib, Nabil ;
Strumpf, Robert K. ;
Schulman, Steven P. ;
Gerstenblith, Gary ;
DeMaria, Anthony N. ;
Denktas, Ali E. ;
Gammon, Roger S. ;
Hermiller, James B., Jr. ;
Reisman, Mark A. ;
Schaer, Gary L. ;
Sherman, Warren .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (24) :2277-2286
[22]   Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction - Result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial [J].
Ripa, RS ;
Jorgensen, E ;
Wang, YZ ;
Thune, JJ ;
Nilsson, JC ;
Sondergaard, L ;
Johnsen, HE ;
Kober, L ;
Grande, P ;
Kastrup, J .
CIRCULATION, 2006, 113 (16) :1983-1992
[23]   The role of a structured exercise training program on cardiac structure and function after acute myocardial infarction: study protocol for a randomized controlled trial [J].
Fontes-Carvalho, Ricardo ;
Sampaio, Francisco ;
Teixeira, Madalena ;
Gama, Vasco ;
Leite-Moreira, Adelino F. .
TRIALS, 2015, 16
[24]   Assessment of the safety and efficacy of the novel tetrapeptide ITF-1697 on infarct size after primary PTCA in acute myocardial infarction: A randomised, placebo-controlled pilot trial [J].
Syeda B. ;
Kiss K. ;
Modarressy K. ;
Schönau K. ;
Schukro C. ;
Derntl M. ;
Laggner A. ;
Sochor H. ;
Glogar D. .
Drugs in R & D, 2004, 5 (3) :141-151
[25]   Granulocyte colony-stimulating factor attenuates left ventricular remodelling after acute anterior STEMI: results of the single-blind, randomized, placebo-controlled multicentre STem cEll Mobilization in Acute Myocardial Infarction (STEM-AMI) Trial [J].
Achilli, Felice ;
Malafronte, Cristina ;
Lenatti, Laura ;
Gentile, Francesco ;
Dadone, Viola ;
Gibelli, Giuseppe ;
Maggiolini, Stefano ;
Squadroni, Lidia ;
Di Leo, Claudio ;
Burba, Ilaria ;
Pesce, Maurizio ;
Mircoli, Luca ;
Capogrossi, Maurizio C. ;
Di Lelio, Alessandro ;
Camisasca, Paola ;
Morabito, Alberto ;
Colombo, Gualtiero ;
Pompilio, Giulio .
EUROPEAN JOURNAL OF HEART FAILURE, 2010, 12 (10) :1111-1121
[26]   Efficacy and Safety of Shenqisuxin Granule for Non-ST-segment Elevation Acute Coronary Syndrome: Study Protocol for a Randomized, Double-Blinded, Placebo-Controlled Trial [J].
Wu, Xiaoping ;
Guo, Ming ;
Shi, Shihua ;
Shi, Shengnan ;
Deng, Yanping ;
Wang, Shenglan ;
Wang, Yabing ;
Wang, Peili ;
Chen, Keji .
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
[27]   LateTIME A Phase-II, Randomized, Double-Blinded, Placebo-Controlled, Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells 2 to 3 Weeks after Acute Myocardial Infarction [J].
Traverse, Jay H. ;
Henry, Timothy D. ;
Vaughan, Douglas E. ;
Ellis, Stephen G. ;
Pepine, Carl J. ;
Willerson, James T. ;
Zhao, David X. M. ;
Simpson, Lara M. ;
Penn, Marc S. ;
Byrne, Barry J. ;
Perin, Emerson C. ;
Gee, Adrian P. ;
Hatzopoulos, Antonis K. ;
McKenna, David H. ;
Forder, John R. ;
Taylor, Doris A. ;
Cogle, Christopher R. ;
Baraniuk, Sarah ;
Olson, Rachel E. ;
Jorgenson, Beth C. ;
Sayre, Shelly L. ;
Vojvodic, Rachel W. ;
Gordon, David J. ;
Skarlatos, Sonia I. ;
Moye, Lemuel A. ;
Simari, Robert D. .
TEXAS HEART INSTITUTE JOURNAL, 2010, 37 (04) :412-420
[28]   Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol [J].
Niccoli, Giampaolo ;
D'amario, Domenico ;
Spaziani, Cristina ;
Cosentino, Nicola ;
Marino, Marcello ;
Rigattieri, Stefano ;
Lo Schiavo, Paolo ;
De Vita, Maria Rosaria ;
Tarantino, Fabio ;
Bartorelli, Antonio ;
Fabbiocchi, Franco ;
Prati, Francesco ;
Imola, Fabrizio ;
Valgimigli, Marco ;
Ferrari, Roberto ;
Crea, Filippo .
JOURNAL OF CARDIOVASCULAR MEDICINE, 2009, 10 (07) :585-592
[29]   The impact of oral nicorandil pre-treatment on ST resolution and clinical outcome of patients with acute ST-segment elevation myocardial infarction undergoing primary coronary angioplasty: A randomized placebo controlled trial [J].
Akbari, Behnaz ;
Ghaffari, Samad ;
Aslanabadi, Naser ;
Sohrabi, Bahram ;
Pourafkari, Leili ;
Akbarzadeh, Fariborz ;
Javadzadegan, Hasan ;
Separham, Ahmad ;
Sehati, Malihe .
JOURNAL OF CARDIOVASCULAR AND THORACIC RESEARCH, 2020, 12 (02) :90-96
[30]   Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With ST-Segment Elevation Myocardial Infarction and Left Ventricular Dysfunction: A Multicenter Randomized, Double-Blind, and Placebo-Controlled Clinical Trial [J].
Fernandez-Aviles, Francisco ;
Sanz-Ruiz, Ricardo ;
Bogaert, Jan ;
Casado Plasencia, Ana ;
Gilaberte, Inmaculada ;
Belmans, Ann ;
Eugenia Fernandez-Santos, Maria ;
Charron, Dominique ;
Mulet, Miguel ;
Yotti, Raquel ;
Palacios, Itziar ;
Luque, Manuel ;
Sadaba, Rafael ;
Alberto San Roman, J. ;
Larman, Mariano ;
Sanchez, Pedro L. ;
Sanchis, Juan ;
Jimenez, Manuel F. ;
Claus, Piet ;
Al-Daccak, Reem ;
Lombardo, Eleuterio ;
Luis Abad, Jose ;
DelaRosa, Olga ;
Corcostegui, Lucia ;
Bermejo, Javier ;
Janssens, Stefan .
CIRCULATION RESEARCH, 2018, 123 (05) :579-589